Cargando…
Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs
A number of important drugs used to treat cancer—many of which serve as the backbone of modern chemotherapy regimens—have outdated prescribing information in their drug labeling. The Food and Drug Administration is undertaking a pilot project to develop a process and criteria for updating prescribin...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066705/ https://www.ncbi.nlm.nih.gov/pubmed/32162805 http://dx.doi.org/10.1634/theoncologist.2019-0698 |
_version_ | 1783505293699710976 |
---|---|
author | Balogh, Erin P. Bindman, Andrew B. Eckhardt, S. Gail Halabi, Susan Harvey, R. Donald Jaiyesimi, Ishmael Miksad, Rebecca Moses, Harold L. Nass, Sharyl J. Schilsky, Richard L. Sun, Steven Torrente, Josephine M. Warren, Katherine E. |
author_facet | Balogh, Erin P. Bindman, Andrew B. Eckhardt, S. Gail Halabi, Susan Harvey, R. Donald Jaiyesimi, Ishmael Miksad, Rebecca Moses, Harold L. Nass, Sharyl J. Schilsky, Richard L. Sun, Steven Torrente, Josephine M. Warren, Katherine E. |
author_sort | Balogh, Erin P. |
collection | PubMed |
description | A number of important drugs used to treat cancer—many of which serve as the backbone of modern chemotherapy regimens—have outdated prescribing information in their drug labeling. The Food and Drug Administration is undertaking a pilot project to develop a process and criteria for updating prescribing information for longstanding oncology drugs, based on the breadth of knowledge the cancer community has accumulated with the use of these drugs over time. This article highlights a number of considerations for labeling updates, including selecting priorities for updating; data sources and evidentiary criteria; as well as the risks, challenges, and opportunities for iterative review to ensure prescribing information for oncology drugs remains relevant to current clinical practice. |
format | Online Article Text |
id | pubmed-7066705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70667052020-04-06 Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs Balogh, Erin P. Bindman, Andrew B. Eckhardt, S. Gail Halabi, Susan Harvey, R. Donald Jaiyesimi, Ishmael Miksad, Rebecca Moses, Harold L. Nass, Sharyl J. Schilsky, Richard L. Sun, Steven Torrente, Josephine M. Warren, Katherine E. Oncologist Commentaries A number of important drugs used to treat cancer—many of which serve as the backbone of modern chemotherapy regimens—have outdated prescribing information in their drug labeling. The Food and Drug Administration is undertaking a pilot project to develop a process and criteria for updating prescribing information for longstanding oncology drugs, based on the breadth of knowledge the cancer community has accumulated with the use of these drugs over time. This article highlights a number of considerations for labeling updates, including selecting priorities for updating; data sources and evidentiary criteria; as well as the risks, challenges, and opportunities for iterative review to ensure prescribing information for oncology drugs remains relevant to current clinical practice. John Wiley & Sons, Inc. 2019-12-08 2020-03 /pmc/articles/PMC7066705/ /pubmed/32162805 http://dx.doi.org/10.1634/theoncologist.2019-0698 Text en © 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Commentaries Balogh, Erin P. Bindman, Andrew B. Eckhardt, S. Gail Halabi, Susan Harvey, R. Donald Jaiyesimi, Ishmael Miksad, Rebecca Moses, Harold L. Nass, Sharyl J. Schilsky, Richard L. Sun, Steven Torrente, Josephine M. Warren, Katherine E. Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs |
title | Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs |
title_full | Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs |
title_fullStr | Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs |
title_full_unstemmed | Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs |
title_short | Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs |
title_sort | challenges and opportunities to updating prescribing information for longstanding oncology drugs |
topic | Commentaries |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066705/ https://www.ncbi.nlm.nih.gov/pubmed/32162805 http://dx.doi.org/10.1634/theoncologist.2019-0698 |
work_keys_str_mv | AT balogherinp challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs AT bindmanandrewb challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs AT eckhardtsgail challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs AT halabisusan challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs AT harveyrdonald challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs AT jaiyesimiishmael challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs AT miksadrebecca challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs AT mosesharoldl challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs AT nasssharylj challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs AT schilskyrichardl challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs AT sunsteven challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs AT torrentejosephinem challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs AT warrenkatherinee challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs |